← Back to Search
Physiologically Based Pharmacokinetic Modeling
H. Clewell, M. Reddy, T. Lavé, M. Andersen
Published 2010 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
In the pharmaceutical area, the use of physiologically based pharmacokinetic (PBPK) models was limited in drug development due to the perceived mathematical complexity of the models and the labor-intensive input data required. However, advances in the prediction of hepatic metabolism and tissue distribution from in vitro and in silico data have made the use of these models more attractive, providing the opportunity to gain mechanistic insight into the compound's properties. This article provides information necessary to understanding the application of PBPK models in preclinical drug development and advances in the available tools. Keywords: physiologically based pharmacokinetic (PBPK) models; drug development; preclinical data; drug metabolism
This paper references
Quantitative Relations in the Physiological Constitutions of Mammals.
E. Adolph (1949)
Preliminary model for methotrexate pharmacokinetics.
K. B. Bischoff (1970)
K. B. Bischoff (1971)
Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces.
B. N. Swanson (1981)
Saturable metabolism and its relationship to toxicity.
M. Andersen (1981)
Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling.
J. Collins (1982)
Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies.
G. Lam (1982)
Physiologically based pharmacokinetic modeling: principles and applications.
L. E. Gerlowski (1983)
Physiologically based pharmacokinetics and the risk assessment process for methylene chloride.
M. Andersen (1987)
Cisplatin pharmacokinetics: applications of a physiological model.
F. Farris (1988)
Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
J. Fisher (1989)
A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid.
E. O'flaherty (1992)
Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development
C. Peck (1992)
Dose-dependent pharmacokinetics of all-trans-retinoic acid.
P. Adamson (1992)
Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment.
M. Andersen (1993)
Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing.
H. Clewell (1993)
A mechanistic model of effects of dioxin on gene expression in the rat liver.
M. Kohn (1993)
Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics.
J. Houston (1994)
A Partition Coefficient Determination Method for Nonvolatile Chemicals in Biological Tissues
G. Jepson (1994)
Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride.
H. Clewell (1994)
An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data.
P. Poulin (1995)
An Approach for Incorporating Tissue Composition Data Into Physiologically Based Pharmacokinetic Models
M. Pelekis (1995)
A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals
P. Poulin (1995)
Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk.
H. Clewell (1996)
A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride.
G. Semino (1997)
Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Ronald P. Brown (1997)
A physiologically based pharmacokinetic model for retinoic acid and its metabolites.
H. Clewell (1997)
Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.
J. Houston (1997)
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.
K. Ito (1998)
Drug Interactions of HIV Protease Inhibitors
L. Malaty (1999)
Mathematical models in percutaneous absorption
M. Roberts (1999)
Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations
T. Lavé (1999)
A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.
P. Poulin (2000)
Early ADME in support of drug discovery: the role of metabolic stability studies.
T. Thompson (2000)
Pharmacokinetic models of dermal absorption.
K. D. McCarley (2001)
Predicting the impact of physiological and biochemical processes on oral drug bioavailability.
B. Agoram (2001)
Estimating the starting dose for entry into humans: principles and practice
B. Reigner (2001)
Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.
P. Poulin (2001)
Prediction of pharmacokinetic properties using experimental approaches during early drug discovery.
P. Chaturvedi (2001)
Prediction of Hepatic Metabolic Clearance
J. Zuegge (2001)
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
P. Poulin (2002)
Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA.
N. Parrott (2002)
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.
P. Poulin (2002)
Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds.
D. Plowchalk (2002)
Whole Body Pharmacokinetic Models
I. Nestorov (2003)
ADMET in silico modelling: towards prediction paradise?
H. van de Waterbeemd (2003)
Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.
Frank-Peter Theil (2003)
The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.
J. Lin (2003)
Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise.
M. Reddy (2003)
Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.
O. Luttringer (2003)
The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans
T. Lave (2004)
Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience
K. Blesch (2004)
A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats
S. Willmann (2004)
The Many Roles of Computation in Drug Discovery
W. L. Jorgensen (2004)
Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus
G. Tucker (2004)
Physiological Parameters in Laboratory Animals and Humans
B. Davies (2004)
Lumping of Whole-Body Physiologically Based Pharmacokinetic Models
I. Nestorov (2004)
Introduction: A Historical Perspective of the Development and Applications of PBPK Models
M. Andersen (2005)
Dermal Exposure Models
M. Reddy (2005)
Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man.
N. Parrott (2005)
An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.
N. Parrott (2005)
Metals and Inorganic Compounds
J. Campain (2005)
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.
Trudy Rodgers (2005)
Development and Application of Physiologically Based Pharmacokinetic‐Modeling Tools to Support Drug Discovery
Christian Lüpfert (2005)
A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES
R. Riley (2005)
A review of the applications of physiologically based pharmacokinetic modeling
K. Himmelstein (2005)
The use and abuse of models
A. Rescigno (2005)
R. Dedrick (2005)
Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study
I. Gueorguieva (2005)
Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed.
L. Aarons (2005)
In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models
J. Lin (2005)
Genomic approaches to drug discovery.
D. Ricke (2006)
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
H. Jones (2006)
Integrating invitro ADMET data through generic physiologically based pharmacokinetic models
D. Leahy (2006)
Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.
Trudy Rodgers (2006)
In vitro ADME medium/high-throughput screening in drug preclinical development.
A. Lahoz (2006)
Physiologically based pharmacokinetic modeling as a tool for drug development
S. B. Charnick (2006)
Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
H. Cai (2006)
APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA
F. Brightman (2006)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Z. Barter (2007)
Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002)
M. Rowland (2008)
This paper is referenced by
Evaluation of a Physiologically Based Pharmacokinetic (PBPK) Model Used to Develop Health Protective Levels for Trichloroethylene
T. Covington (2017)
Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data
T. Ericsson (2017)
Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations
M. Almukainzi (2017)
Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver
M. Andersen (2017)
Toxicological profile for 1-Bromopropane
N. Roney (2017)
Toxicological profile for parathion
S. Keith (2017)
Nanoparticle Pharmacokinetics and Toxicokinetics
Ashutosh Kumar Singh (2016)
A physiologically-based pharmacokinetic model for the antibiotic ertapenem.
M. Joyner (2016)
Draft toxicological profile for JP-5, JP-8, and jet A fuels
J. Risher (2016)
Computational Fluid-Particle Dynamics Modeling for Unconventional Inhaled Aerosols in Human Respiratory Systems
Y. Feng (2016)
Development of a toxicokinetic model for the honey bee (Apis mellifera) colony for the use in risk assessment
K. Hörig (2016)
Fuzzy Physiologically Based Pharmacokinetic (PBPK) Model of Chloroform in Swimming Pools
R. Dyck (2016)
The evolution of inhaled particle dose modeling: A review
R. Phalen (2016)
Physicologically Based Toxicokinetic Models of Tebuconazole and Application in Human Risk Assessment.
Svava Ósk Jónsdóttir (2016)
Formulation and topical delivery of niosomes and proniosomes containing carnosine
Martha Maria Lundie (2016)
An integrated QSAR-PBK/D modelling approach for predicting detoxification and DNA adduct formation of 18 acyclic food-borne α,β-unsaturated aldehydes.
R. Kiwamoto (2015)
Physiologically based in silico modelling to examine DNA adduct formation by different food-borne a,ß-unsaturated aldehydes at realistic low dietary exposure levels
R. Kiwamoto (2015)
Toxicokinetics and absolute oral bioavailability of melamine in broiler chickens.
S. Poapolathep (2015)
Biological monitoring guidance values for chemical incidents.
John Cocker (2014)
Correlating in vitro data to in vivo findings for risk assessment.
A. S. Bale (2014)
Understanding temporality in human concentrations of organic contaminants -Considering human concentrations over time and through life in perspective of historic production and use
T. Nøst (2014)
Predicting passive and active tissue:plasma partition coefficients: interindividual and interspecies variability.
Christopher D. Ruark (2014)
Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement
K. Grime (2013)
Développement de modèles prédictifs de la toxicocinétique de substances organiques
T. Peyret (2013)
INVESTIGATIONS ON VENTILATION EQUATION STRUCTURE IN PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF INHALED TOXICANTS
K. Yokley (2013)
Physiologically Based Pharmacokinetic Modeling: A Tool for Understanding ADMET Properties and Extrapolating to Human
M. Reddy (2013)
Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.
M. E. Meek (2013)
Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms
J. Caldwell (2012)
Modeling Drug- and Chemical-Induced Hepatotoxicity with Systems Biology Approaches
S. Bhattacharya (2012)
Age-Specific Absolute and Relative Organ Weight Distributions For B6C3F1 Mice
Dale J Marino (2012)
Legislative Measures for In Vitro–In Vivo Correlations and Pharmacokinetic Modeling
V. Pillay (2012)
Use of partition coefficients in flow-limited physiologically-based pharmacokinetic modeling
M. D. Thompson (2012)See more